Wednesday evening during the Mad Money program Jim Cramer mentioned Johnson & Johnson (JNJ) as a company that was less risky than some of the vaccine makers that have gotten frothy lately. Let's check out their charts.
More from Investing
Concerns about the action being overheated remain, but rotational action keeps the momentum going.
Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.
IPOs in recent months have done extremely well -- not so GDRX.
Competition from AMD and ARM CPU developers looks set to take a toll over the next two years. But Intel could be in better shape in 2023 if its new CEO is ready to make some tough choices.